Skip to content
User

Ole Andreas Halvorsen

Viking Global Investors

Ole Andreas Halvorsen Intercept Pharmaceuticals Inc stake

total: 670

Viking Global Investors ICPT trades

Total transactions:
3
New positions:
1
Sold out:
1
Reduced:
1
Held since:
2014 Q1
Held for:
2 quarters
Latest activity:
2014 Q3
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Intercept Pharmaceuticals Inc (ICPT) shares. To date, the estimated cost basis is nearly $329.79 for "buy" trades and estimated average "sell" price is $236.63. Viking Global Investors first purchased ICPT in 2014 Q1, initially acquiring 454,917 shares. Since the initial investment in Intercept Pharmaceuticals Inc (ICPT), Viking Global Investors has made 2 more transactions.

When did Ole Andreas Halvorsen sell Intercept Pharmaceuticals Inc (ICPT)?

Ole Andreas Halvorsen sold off the entire Intercept Pharmaceuticals Inc (ICPT) position in 2014 Q3.

When did Ole Andreas Halvorsen buy Intercept Pharmaceuticals Inc (ICPT)?

Ole Andreas Halvorsen first invested in Intercept Pharmaceuticals Inc (ICPT) in 2014 Q1 at the reported quarter-end price of $329.79 per share.

What's the cost basis of Viking Global Investors's ICPT stake?

The estimated cost basis for Intercept Pharmaceuticals Inc (ICPT) stake is around $329.79 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$329.79
Weighted AVG sell price:
$236.63

Ole Andreas Halvorsen's historical trades in Intercept Pharmaceuticals Inc

3 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2014 Q3
0.00%
$236.63
-100% (-208,077)
2014 Q2
0.21%
$236.63
-54.26% (-246,840)
2014 Q1
0.63%
$329.79
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.